Eris Lifesciences to target insulin, semaglutide mkt opportunities in FY26

Eris Lifesciences to leverage Novo Nordisk's exit and semaglutide patent expiry, with cartridge capacity and diabetes-focused products planned for commercialisation in FY26

Ahmedabad-based Eris Lifesciences is looking to target opportunities in the nearly ₹5,000-crore Indian insulin market after Danish drugmaker Novo Nordisk announced a withdrawal of its insulin products in April this year.

 

For Q1FY26, Eris Lifesciences recorded a 40 per cent year-on-year (Y-o-Y) rise in consolidated profit after tax (PAT) to ₹125 crore. Revenue rose to ₹773 crore during the June quarter against ₹720 crore in the year-ago period.

 

“We expect that Novo’s cartridge inventory in the market will run out by October. So this market opportunity is something that one can start monetising from the November-December time frame,” the company’s